Anti-Human IL5 Recombinant Antibody (Mepolizumab) (CAT#: TAB-031)

Recombinant monoclonal antibody to Human IL5. Mepolizumab (proposed trade name Bosatria) is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5), and is used to treat certain kinds of asthma and white blood cell diseases. Recent studies have concluded that mepolizumab may improve exacerbations in patients with severe eosinophilic asthma, an adult-onset asthma which represents less than 5% of all asthma. IL-5 is a chemical messenger in the immune system that stimulates the growth of eosinophils. In eosinophilic asthma, eosinophils are present in the lungs. When mepolizumab was given to people with eosinophilic asthma, it eliminated eosinophils from the bloodstream,and reduced eosinophils in the lungs and bone marrow. Mepolizumab also reduced the number of asthma exacerbations, and reduced the need for corticosteroids.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Anti-interleukin (IL)-5 (mepolizumab) decreases β2 but not β1 integrin activation on blood eosinophils.

Figure 1 Anti-interleukin (IL)-5 (mepolizumab) decreases β2 but not β1 integrin activation on blood eosinophils.

Reactivity of monoclonal antibody (A) KIM-127 (to the intermediate-activity state of β2 integrin), and (b) N29 (to the intermediate-activity state of β1 integrin) on blood eosinophils before (green) and after (blue) anti-IL-5 mepolizumab administration. Red, isotype control. A representative subject with mild allergic asthma from Ref. (34).

Johansson, M. W. . (2017). Eosinophil activation status in separate compartments and association with asthma. Frontiers in Medicine, 4, 75-.

Figure 2 Photomicrographs of esophageal biopsies before and after anti–IL-5 therapy. Biopsies from the distalesophagus before (A, B) and after (C, D) anti–IL-5 therapy (mepolizumab).

Figure 2 Photomicrographs of esophageal biopsies before and after anti–IL-5 therapy. Biopsies from the distalesophagus before (A, B) and after (C, D) anti–IL-5 therapy (mepolizumab).

The photomicrographs have been selected to demonstrate representative well oriented (A, C) and typical biopsies with maximal tissue pathology (B, D). Note the presence of marked eosinophilic inflammation and epithelial hyperplasia before (week 8) and reduced eosinophilic inflammation and epithelial hyperplasia after (week 20) anti–IL-5. The photomicrographs were taken from patient number 4. Original magnification, 3400.

Osterman, & M. (2007). Anti-il-5 (mepolizumab) therapy for eosinophilic esophagitis. Yearbook of Gastroenterology, 2007, 169.


Specifications

  • Immunogen
  • Recombinant human IL5.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen
  • Species Reactivity
  • Human
  • Applications
  • IF, IP, Neut, FuncS, ELISA, FC, ICC
  • Trade name
  • bosatria
  • CAS
  • 196078-29-2
  • Generic Name
  • Mepolizumab
  • Biological Half-Life
  • 20 days
  • ATC Code
  • L04AC06
  • Related Disease
  • Asthma

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.

Applications

  • Application Notes
  • The IL5 antibody has been reported in applications of Activ, IHC.

Target

  • Alternative Names
  • Mepolizumab;bosatria;196078-29-2;SB-240563;IL5;interleukin 5 (colony-stimulating factor, eosinophil);interleukin-5;B cell differentiation factor I;EDF;eosinophil differentiation factor;IL 5;interleukin 5;T cell replacing factor;TRF;T-cell replacing factor

Related Resources

  • Biosimilar Overview
  • Related Diseases
Please refer to Mepolizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Mepolizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Mepolizumab"

Afuco™ Anti-IL5 ADCC Recombinant Antibody (Mepolizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human IL5. Mepolizumab (proposed trade name Bosatria) is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5), and is used to treat certain kinds of asthma and white blood cell diseases. Recent studies have concluded that mepolizumab may improve exacerbations in patients with severe eosinophilic asthma, an adult-onset asthma which represents less than 5% of all asthma. IL-5 is a chemical messenger in the immune system that stimulates the growth of eosinophils. In eosinophilic asthma, eosinophils are present in the lungs. When mepolizumab was given to people with eosinophilic asthma, it eliminated eosinophils from the bloodstream,and reduced eosinophils in the lungs and bone marrow. Mepolizumab also reduced the number of asthma exacerbations, and reduced the need for corticosteroids.

See other products for "IL5"

Humanized Antibody

CAT Product Name Application Type
TAB-136 Anti-Human IL5 Recombinant Antibody (Reslizumab) Neut, ELISA, IF, IP, FuncS, FC, IHC IgG4

Recombinant Antibody

Neutralizing Antibody

CAT Product Name Application Type
NEUT-1437CQ Mouse Anti-IL5 Recombinant Antibody (clone CBL632) ELISA, Neut Mouse IgG2a
NEUT-1438CQ Mouse Anti-IL5 Recombinant Antibody (clone CBL420) Neut Mouse IgG1
NEUT-1439CQ Rat Anti-IL5 Recombinant Antibody (clone CBL900) ELISA, FC, IF, Neut, WB Rat IgG1, κ
NEUT-1440CQ Rat Anti-IL5 Recombinant Antibody (clone JES1-39D10) ELISA, ELISPOT, Neut, ICFC, IHC, WB Rat IgG2a, κ
NEUT-1441CQ Rat Anti-IL5 Recombinant Antibody (clone JES1-5A10) ELISA, ELISPOT, Neut Rat IgG2a, κ

Blocking Antibody

CAT Product Name Application Type
NEUT-1443CQ Rat Anti-IL5 Recombinant Antibody (clone TRFK4) ELISA, Inhib, WB Rat IgG2a

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-031 Afuco™ Anti-IL5 ADCC Recombinant Antibody (Mepolizumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-136 Afuco™ Anti-IL5 ADCC Recombinant Antibody (Reslizumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-031. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare